Harmony Biosciences Holdings, Inc.
For the period ended Sep 30, 2026. Filed Nov 4, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 4, 2026
HRMY$33.55-0.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets (Unaudited)
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS
| | | | | | | |
|---|---|---|---|---|---|---|
| · · September 30, · · December 31, | ||||||
| · · 2026 · · 2025 | ||||||
| ASSETS · · · · | ||||||
| CURRENT ASSETS: · · · · | ||||||
| Cash and cash equivalents | | $647,099 | | $752,502 | ||
| Investments, short-term | | | 124,039 | | | 22,838 |
| Trade receivables, net | | 127,739 | | 96,787 | ||
| Inventory, net | | 5,871 | | 5,357 | ||
| Prepaid expenses | | 18,101 | | 16,014 | ||
| Other current assets | | 11,981 | | 13,516 | ||
| Total current assets | | 934,830 | | 907,014 | ||
| NONCURRENT ASSETS: | | | | | ||
| Investments, long-term | | | 280,467 | | | 107,127 |
| Intangible assets, net | | 71,535 | | 89,418 | ||
| Deferred tax asset | | | 161,365 | | | 149,699 |
| Other noncurrent assets | | 30,048 | | 18,373 | ||
| Total noncurrent assets | | 543,415 | | 364,617 | ||
| TOTAL ASSETS | | $1,478,245 | | $1,271,631 | ||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | | | | | ||
| CURRENT LIABILITIES: | | | | | ||
| Trade payables | | $26,919 | | $17,693 | ||
| Accrued compensation | | 14,886 | | 18,443 | ||
| Accrued expenses | | 208,062 | | 191,039 | ||
| Current portion of long-term debt | | | 20,000 | | | 20,000 |
| Other current liabilities | | 1,675 | | 4,957 | ||
| Total current liabilities | | 271,542 | | 252,132 | ||
| NONCURRENT LIABILITIES: | | | | | ||
| Long-term debt, net | | 129,104 | | 143,663 | ||
| Other noncurrent liabilities | | 5,367 | | 5,618 | ||
| Total noncurrent liabilities | | 134,471 | | 149,281 | ||
| TOTAL LIABILITIES | | 406,013 | | 401,413 | ||
| COMMITMENTS AND CONTINGENCIES (Note 12) | | | | | ||
| STOCKHOLDERS’ EQUITY: | | | | | ||
| Common stock—$0.00001 par value; 500,000,000 shares authorized at September 30, 2026 and December 31, 2025, respectively; 58,720,081 and 57,726,170 shares issued and outstanding at September 30, 2026, and December 31, 2025, respectively | | 1 | | 1 | ||
| Additional paid in capital | | 757,153 | | 708,968 | ||
| Accumulated other comprehensive (loss) income | | | (1,940) | | | 346 |
| Retained earnings | | 317,018 | | 160,903 | ||
| TOTAL STOCKHOLDERS’ EQUITY | | 1,072,232 | | 870,218 | ||
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | | $1,478,245 | | $1,271,631 | ||
UNAUDITED CONDENSED CONSOLIDATED
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.